TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00824343

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: P276-00
Description: For patients to be recruited in amended protocol, P276-00 will be administered to all subjects at a dose of 144 mg/m2/day as i.v infusion in 200 ml of 5% dextrose over 30 minutes from day 1 to day 5 and from day 8 to day 12 in each 21 day cycle. Subjects will receive treatment till progression of disease or till unacceptable toxicity. All subjects will be followed up for survival status till one year of initiation of protocol treatment.
Study: NCT02954510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ferumoxytol
Description: ferumoxytol will assess patency of coronary arteries
Study: NCT03860428

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: In the medical treatment arm the in-tention is to close the ductus arteriosus.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol
Description: In the medical treatment arm the in-tention is to close the ductus arteriosus.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Expectant Management
Description: Expectative PDA management is character-ized as 'watchful waiting'. No intervention is initiated with the intention to close a PDA.
Study: NCT02790814

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Moyo strap-on
Description: Continous measurements

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hand-held fetoscope
Description: Intermittent measurements
Study: NCT02517372

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CRD007
Study: NCT03815097

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mapleson circuit and nasal trumpet
Description: The Mapleson Circuit is a breathing system used to deliver oxygen and remove carbon dioxide during anesthesia. It consists of fresh oxygen flow, a reservoir bag, an expiratory valve, tubing, and a connection to the patient. There are different types of Mapleson circuits depending on the different arrangements of its components. We plan to use a Mapleson D circuit attached to a nasal trumpet via a connector.
Study: NCT00587483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine is a class I (sodium channel block) antiarrhythmic drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amiodarone
Description: 300 mg
Study: NCT04299009

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bright light therapy glasses
Description: Bright light therapy delivered through glasses

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Bright light therapy glasses
Description: Bright light therapy delivered through glasses
Study: NCT00587483

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT00697515

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LDX
Description: oral, 30, 50, or 70 mg once-daily for 4 weeks during dose optimization, and then for 1 week during each crossover during the adult workplace environment setting

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo administered once-daily for one week during the adult workplace environment setting
Study: NCT04029714

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Active Surveillance
Description: Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Active Surveillance
Description: Active monitoring of prostate cancer and curative treatment if there are signs of tumor progression.
Study: NCT04384510

Intervention type: PROCEDURE
Intervention: Planned Cesarean hysterectomy
Description: This procedure refers to planned delivery of the fetus through Cesarean incision, leaving the placenta in situ and proceeding with hysterectomy

Intervention type: PROCEDURE
Intervention: Conservative management
Description: This term describes a single or combined intervention of uterine artery ligation, internal iliac artery ligation, prophylactic balloon placement in the aorta or internal iliac artery, uterine artery embolization, compression sutures, or excision and reconstruction of uterine wall
Study: NCT03897400

Intervention type: OTHER
Intervention: AMH levels in young women with crohn's disease will be considered.
Description: Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.

Intervention type: OTHER
Intervention: AMH levels in young women with crohn's disease will be considered.
Description: Ovarian Reserve in Young Women of Reproductive Age with Crohn's Disease;Blood will be taken from both the study and control groups and the AMH level will be evaluated.
Study: NCT01382017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 200 or 400 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: Lacosamide 200 or 400 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carbamazepine
Description: Carbamazepine 600 mg
Study: NCT03599050

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audiotaped Counseling Session
Description: Patients and nurses will complete audio taped counseling session at least 3 months following the baseline visit. Patients will rate quality of nurse communication skills
Study: NCT01623323

Intervention type: DRUG
Group type: OTHER
Intervention: Fluticasone Propionate
Description: Fluticasone Propionate 400 μg
Study: NCT04341909

Intervention type: PROCEDURE
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography

Intervention type: PROCEDURE
Intervention: ERCP
Description: endoscopic retrograde cholangiopancreatography
Study: NCT01619007

Intervention type: DRUG
Intervention: Rivaroxaban (Xarelto, BAY59-7939)
Description: Patients who will be treated for an acute deep vein thrombosis (DVT) with rivaroxaban
Study: NCT03045887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation
Study: NCT03505736

Intervention type: BIOLOGICAL
Intervention: Adenosine
Description: Given IV

Intervention type: PROCEDURE
Intervention: Magnetic Resonance Imaging
Description: Undergo CMR imaging

Intervention type: DRUG
Intervention: Regadenoson
Description: Given IV

Intervention type: PROCEDURE
Intervention: Stress Management Therapy
Description: Undergo stress test
Study: NCT03580928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venetoclax
Description: Venetoclax is an oral drug that blocks the function of a protein called BCL-2. CLL cancer cells are thought to depend on the BCL-2 protein for their survival. By blocking BCL-2, venetoclax may kill cancer cells or stop them from growing.
Study: NCT03045887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 50 μg
Description: GSK2292767 50 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation
Study: NCT03580928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab is a type of drug called a monoclonal antibody. It targets a protein CD20 on the surface of the CLL cell, causing it to die

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib is a type of drug called a kinase inhibitor. It blocks a type of protein called Bruton Tyrosine Kinase (BTK) that helps CLL cells live and grow
Study: NCT03045887

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2292767 500 μg
Description: GSK2292767 500 μg blended with lactose and magnesium stearate per blister as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Lactose as powder for inhalation
Study: NCT01619007

Intervention type: DRUG
Intervention: Standard of care
Description: Patients who will be treated for an acute deep vein thrombosis (DVT) with current standard of care comprising e.g. of initial treatment with low-molecular weight heparin or fondaparinux, followed by oral Vitamin-K antagonist for at least 3 months
Study: NCT00837044

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Treximet
Description: Treximet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Migraine rescue medication of choice
Description: Migraine rescue medication of choice
Study: NCT04388748

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress Management and Resiliency Training for Depression (SMART-D) Therapy
Description: 6 SMART-D group therapy sessions over 8 weeks
Study: NCT02312544

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: OTX-TP
Description: OTX-TP and placebo drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Timolol
Description: Timolol drops and placebo punctum plug
Study: NCT03897036

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CX-4945
Description: API powder-in-capsule in 200 mg strength
Study: NCT00410306

Intervention type: DRUG
Intervention: Testosterone Undecanoate (Nebido, BAY86-5037)
Description: Patients from routine practice
Study: NCT02718040

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Emervel Classic and/or Deep Treatment Group
Description: Severity of Wrinkle Severity treated by product type:~Emervel Classic:~Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 2/2, 2/3 or 3/3; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 2/2, 2/3 or 3/3~Emervel Deep Nasolabial Folds (NLFs): Wrinkle Severity Rating Scale (WSRS) = 3/3, 3/4 or 4/4; Marionette Lines (MLs): Wrinkle Assessment Scale (WAS) = 3/3, 3/4 or 4/4~Both products may be used in the same subject, but only in different anatomic locations. The same study product should be used within the same wrinkle or fold type (e.g., left and right NLFs treated with the same product)
Study: NCT02660892

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein intake
Description: Oral consumption of eight hourly experimental meals~* 4 tracer free experimental meals containing a mixture of free amino acids and calories from protein free flavoured liquid, protein free cookies and corn oil~* 4 isotopically labeled experimental meals.
Study: NCT06312033

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate
Description: To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estradiol Valerate
Description: To elevate estradiol levels each woman has received 6mg on two consecutive days (total 12mg) of estradiol valerate (Progynova21©)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo (blue-colored hard gelatine capsules completely filled with a mixture of 99.5% mannitol and 0.5% Aerosil (fumed silica)) has been administered (placebo-controlled condition)
Study: NCT04337008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: blood draw
Description: 20 mL blood draw will be performed at J1 et J7

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: blood draw
Description: 20 mL blood draw will be performed at J1 et J7
Study: NCT02286323

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils
Description: Bonfils Intubation Fiberoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bonfils
Description: Bonfils Intubation Fiberoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Description: Direct laryngoscopy using Macintosh Laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Macintosh
Description: Direct laryngoscopy using Macintosh Laryngoscope
Study: NCT00667290

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treadmill exercise
Description: Graded treadmill walking 3 times per week for 3 months
Study: NCT01008462

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Bone Marrow Transplantation
Description: Undergo donor HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Allogeneic Hematopoietic Stem Cell Transplantation
Description: Undergo donor HCT

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Undergo autologous PBSC transplant

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous-Allogeneic Tandem Hematopoietic Stem Cell Transplantation
Description: Undergo autologous-donor tandem HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carmustine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative study

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Given PO

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Peripheral Blood Stem Cell Transplantation
Description: Undergo donor HCT

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Description: Given IV or PO

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total-Body Irradiation
Description: Undergo TBI
Study: NCT04054999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxocobalamin
Description: Hydroxocobalamin (Cyanokit): 5g IV infusion over 15 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylene Blue
Description: Methylene blue (PROVAYBLUETM), 2 mg/kg IV bolus administered over 15 minutes
Study: NCT01908166

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ultrasound elasticity imaging
Description: Undergo ultrasound elastography
Study: NCT03886155

Intervention type: PROCEDURE
Intervention: Biopsy
Description: During clinically-scheduled trigger finger release surgery, soft tissue will be removed from the trigger finger tenosynovium (which may include synovial sheath and subcutaneous fat tissue) and send to pathology to be analyzed with amyloid-specific staining.
Study: NCT00576576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 80 mg a day
Study: NCT03802903

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remo-Wax
Description: topical treatment
Study: NCT01297985

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: BRIDGES Peer-Led Education
Description: The BRIDGES program is a 10-week, manualized education course designed to provide basic education about the etiology and treatment of mental illness, self-help skills, and recovery principles in order to empower participants to return to valued social roles within their communities. BRIDGES is a peer-led program and all instructors are adults with mental illnesses. For this intervention study, the BRIDGES curriculum was modified from a week course to an 8-week course, meeting for 2 1/2 hours once a week.
Study: NCT03577782

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Entyvio (Vedolizumab)
Description: 1. Antiretroviral treatment consisting in Dolutegravir (Tivicay) (50mg) + Tenofovir alafenamide (TAF) (25mg) / Emtricitabina (FTC) (200mg) (Descovy), once daily during 24 weeks.~2. Entyvio (Vedolizumab) (300mg), 7 intravenous infusions at week 0 (baseline) (concomitant with ART onset), 4, 8, 12, 16, 20 and 24.~At week 24 ART and Vedolizumab administration will be interrupted. ART will be resumed if CD4+ T-cell levels drop below 350 CD4+/μL and/or viral load increase above 10e5 HIV-RNA copies/mL (two consecutive measurements).~Patients will be followed up until week 48.
Study: NCT03933566

Intervention type: PROCEDURE
Intervention: Ultrasound-Guided Superficial Cervical Plexus Block
Description: Ultrasound-Guided Superficial Cervical Plexus Block
Study: NCT00104299

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: During the remission induction phase, all participants will receive oral prednisone daily (1 mg/kg/day, not to exceed 80 mg/day). Prednisone tapering will be completed by the Month 6 study visit.
Study: NCT00141297

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-0332991
Description: Dose ranging study - evaluating two oral schedule: (1) 3/1 Schedule - PD-0332991 administered days 1-21 of a 28-day schedule, doses ranging from 25 to 150 mg once daily; (2) 2/1 Schedule - PD-0332991 administered days 1-14 of a 21-days schedule, doses ranging from 100 to 225 mg once daily
Study: NCT00632372

Intervention type: DEVICE
Intervention: Cardiac Resynchronization Therapy
Description: Pacing of the left ventricle to resynchronize ventricular contraction.

Intervention type: DEVICE
Intervention: HeartPOD™ System
Description: Left atrial pressure monitoring.
Study: NCT03501394

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Patients will undergo 4 MRI sessions during NACT treatment. The first scan will take place at treatment baseline before their first cycle of NACT treatment. The second scan will take place following the first treatment cycle prior to the second treatment cycle. Likewise, the third and last scan will take place after the third treatment cycle and sixth (final) treatment cycle prior to surgery. MRI scan sessions will be composed of research scans including diffusion and lipid profiling MR imaging methods and MR spectroscopy (MRS) methods.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Histopathological Analysis
Description: Study specific analysis will be performed on the core biopsy and tissue removed in surgery following the completion of NACT treatment. Standard routine histological analysis will be performed, as well as study specific analysis for immunostaining, grading and slide scan imaging for measurement of cellularity markers.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Questionnaire
Description: Health and demographic information will be collected.
Study: NCT01227694

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autologous MSC knee implantation
Description: Isolation and Ex-Vivo expansion of Mesenchymal stem cells (MSC) obtained from each patient's bone marrow under GMP conditions at Xcelia-División de Terapias avanzadas del Banc de Sang I Teixits. After 21 days, approximately 40 millions of autologous MSC will be implanted in the knee by articular injection.
Study: NCT01626599

Intervention type: DEVICE
Group type: OTHER
Intervention: ProGuardian
Description: The investigational system is composed of a sensor, patch, hub, and caregiver application. The sensor is applied externally during periods of nocturnal sleep for up to 7 nights.~The investigational system:~* is not implantable and no surgical procedure is required for a human subject to use the devices;~* is not for use in supporting or sustaining a human life; and~* is not of substantial importance in diagnosing, curing, mitigating, or treating disease, or otherwise preventing impairment of human health.~* Contains skin-contacting materials made of medical grade materials (e.g. sold for use as surgical or wound care) with well-established biocompatibility testing profiles.
Study: NCT03519815

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ectoin® Eye Spray - Colloidal
Description: eye spray to be applied to the closed eye lid

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Liposomal eye spray Tears Again®
Description: eye spray to be applied to the closed eye lid